drugset / Trial / NCT05702073

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

NCT05702073

Phase 3 Completed 423 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with basal insulin compared to insulin Glargine QD for 26weeks.

Timeline

Start
2023-03-31
Primary completion
2024-06-11
Completion
2024-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject INS068 Protein / enzyme biologic Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous